New Alzeheimer Drugs

Lecanemab (Leqembi) and donanemab (Kisunla) are both new Alzheimer's treatments that aim to slow cognitive decline by addressing the underlying biology of the disease, specifically the buildup of beta-amyloid plaques in the brain. These medications are designed for individuals in the early stages of Alzheimer's, including those with mild cognitive impairment or mild dementia due to Alzheimer's. They have both been approved by the Food and Drug Administration (FDA).

Key Features of Lecanemab and Donanemab:

Targeting Amyloid:

Both drugs target amyloid, a protein that forms plaques in the brain of individuals with Alzheimer's.

• Slow Cognitive Decline:

  Clinical trials have shown that these medications can slow down the rate of cognitive decline, though they do not cure or stop the progression of the disease.

Early Stage Treatment:
They are primarily intended for individuals in the early stages of Alzheimer's, including those with mild cognitive impairment and mild dementia.
• Not a Cure:

  Neither lecanemab nor donanemab is a cure for Alzheimer's. They aim to slow the progression of the disease and help individuals retain their cognitive function for longer.
• Side Effects:

  Side effects of lecanemab can include infusion-related reactions such as fever, flu-like symptoms, nausea, vomiting, dizziness, and changes in heart rate and shortness of breath. Donanemab's side effects are still being studied, but they are expected to be similar to those of lecanemab.
How they Work:
• Lecanemab:

  Lecanemab targets amyloid as it begins to form fibers, according to Alzheimer's Research UK.
• Donanemab:

  Donanemab binds to amyloid once the fibers have clumped together into larger plaques, according to Alzheimer's Research UK.
Important Considerations:
• Not for all stages of Alzheimer's:

  Lecanemab and donanemab have not been studied in individuals with more advanced stages of Alzheimer's or those without clinical symptoms.
• Need for Diagnosis:

  To determine if a person is eligible for treatment with lecanemab or donanemab, they would need to be diagnosed with early Alzheimer's and have confirmation of elevated beta-amyloid.
• 
  
• Further Research:

  Research is ongoing to further understand the long-term effects of these treatments and to explore other potential treatments for Alzheimer's disease.